Erlotinib Pretreatment Improves Photodynamic Therapy of Non–Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms
SM Gallagher-Colombo, J Miller, KA Cengel, ME Putt… - Cancer research, 2015 - AACR
Aberrant expression of the epidermal growth factor receptor (EGFR) is a common
characteristic of many cancers, including non–small cell lung carcinoma (NSCLC), head and …
characteristic of many cancers, including non–small cell lung carcinoma (NSCLC), head and …
EGFR-targeted photodynamic therapy
L Ulfo, PE Costantini, M Di Giosia, A Danielli… - Pharmaceutics, 2022 - mdpi.com
The epidermal growth factor receptor (EGFR) plays a pivotal role in the proliferation and
metastatization of cancer cells. Aberrancies in the expression and activation of EGFR are …
metastatization of cancer cells. Aberrancies in the expression and activation of EGFR are …
In-vivo optical monitoring of the efficacy of epidermal growth factor receptor targeted photodynamic therapy: the effect of fluence rate
W Peng, HS de Bruijn, TLM Ten Hagen, K Berg… - Cancers, 2020 - mdpi.com
Targeted photodynamic therapy (PDT) has the potential to improve the therapeutic effect of
PDT due to significantly better tumor responses and less normal tissue damage. Here we …
PDT due to significantly better tumor responses and less normal tissue damage. Here we …
Preclinical study of a combination of erlotinib and bevacizumab in early stages of unselected non-small cell lung cancer patient-derived xenografts
J Rolff, M Becker, J Merk, J Hoffmann, I Fichtner - Targeted oncology, 2016 - Springer
Background The differential outcomes of clinical studies of the targeted therapies for non-
small cell lung cancer (NSCLC) indicate that better stratification of patients is required. This …
small cell lung cancer (NSCLC) indicate that better stratification of patients is required. This …
5‐aminolaevulinic acid/photo‐dynamic therapy and gefitinib in non‐small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy
I Postiglione, A Chiaviello, SM Aloj… - Cell proliferation, 2013 - Wiley Online Library
Objectives Often, non‐small cell lung cancers (NSCLC) respond only poorly to the tyrosine
kinase inhibitor (TKI) gefitinib, which targets the epidermal growth factor receptor (EGFR) …
kinase inhibitor (TKI) gefitinib, which targets the epidermal growth factor receptor (EGFR) …
Self-Assembly of Erlotinib-Platinum (II) Complexes for Epidermal Growth Factor Receptor-Targeted Photodynamic Therapy
Due to cell mutation and self-adaptation, the application of clinical drugs with early
epidermal growth factor receptor (EGFR)-targeted inhibitors is severely limited. To overcome …
epidermal growth factor receptor (EGFR)-targeted inhibitors is severely limited. To overcome …
Photodynamic targeting of EGFR does not predict the treatment outcome in combination with the EGFR tyrosine kinase inhibitor Tyrphostin AG1478
A Weyergang, O Kaalhus, K Berg - Photochemical & Photobiological …, 2008 - Springer
Photodynamic therapy (PDT) is a selective treatment modality against cancer. PDT is based
on the preferential retention of photosensitizers (PSs), in the tumour and subsequent light …
on the preferential retention of photosensitizers (PSs), in the tumour and subsequent light …
Tumor hypoxia response after targeted therapy in EGFR-mutant non-small cell lung cancer: Proof of concept for FMISO-PET
Hypoxia is associated with resistance to radiotherapy and chemotherapy. Functional
imaging of hypoxia in non-small cell lung cancer (NSCLC) could allow early assessment of …
imaging of hypoxia in non-small cell lung cancer (NSCLC) could allow early assessment of …
Epidermal growth factor receptor-targeted delivery of a singlet-oxygen sensitizer with thermal controlled release for efficient anticancer therapy
J Chen, D Li, B Huo, F Zhang, X Zhao… - Molecular …, 2019 - ACS Publications
Photodynamic therapy (PDT) utilizing light-induced singlet oxygen has achieved attractive
results in anticancer fields; however, its development is hindered by limited light penetration …
results in anticancer fields; however, its development is hindered by limited light penetration …
Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy
GJ Cerniglia, N Pore, JH Tsai, S Schultz, R Mick… - PloS one, 2009 - journals.plos.org
Background Epidermal growth factor receptor (EGFR) inhibitors have shown only modest
clinical activity when used as single agents to treat cancers. They decrease tumor cell …
clinical activity when used as single agents to treat cancers. They decrease tumor cell …